Please login to the form below

Not currently logged in
Email:
Password:

simeprevir

This page shows the latest simeprevir news and features for those working in and with pharma, biotech and healthcare.

Remicade safe from biosimilar competition this year, says J&J

Remicade safe from biosimilar competition this year, says J&J

On the downside, hepatitis C therapy Olysio/Sovriad (simeprevir) continued its decline in the face of strong competition in the marketplace from Gilead and AbbVie, falling 86% to just $32m in

Latest news

More from news
Approximately 9 fully matching, plus 34 partially matching documents found.

Latest Intelligence

  • Taking a strategic approach Taking a strategic approach

    Meanwhile, for Olysio (simeprevir) - one of several new oral drugs that mark a major step forward in hepatitis C treatment - it was an innovative 'pay-if-you-clear' scheme that persuaded

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Medivir names new CEO Medivir names new CEO

    simeprevir). “ Medivir is an attractive company in an exciting phase of its development following the successful market introduction of simeprevir,” he said. “

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Warehousing of HCV patients reaches new high

    Gilead’ s interferon-free product sofosbuvir and Johnson &Johnson’ s simeprevir appear to lead the field – receiving the highest levels of spontaneous and prompted awareness. ... However, Abbvie’ s products ABT 267, ABT 333 and ABT 450 remain

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics